Clinical Trials Logo

Clinical Trial Summary

This phase 2 trial evaluates how well pegylated irinotecan (NKTR-102) works in treating patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or breast cancer (mBC) that has spread to the brain and does not respond to treatment. Pegylated irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


Clinical Trial Description

Primary Objective: For cohort A and Cohort C, to determine the central nervous system (CNS) disease control rate (number of patients with stable disease or partial response or complete response / total number of treated patients) at 12 weeks following treatment with etirinotecan pegol in patients with advanced non-small cell lung cancer (NSCLC) or with metastatic brain cancer (mBC) with refractory brain metastases Secondary Objectives: Cohorts A and C: - To measure the overall disease control rate and response rate for patients receiving study therapy - To measure the systemic (non-CNS) disease control rate and response rate for patients receiving study therapy - To observe the progression free survival of the study population - To observe the overall survival of the study population Cohort B: • To observe CNS and systemic disease control in small cell lung cancer (SCLC) Cohorts A, B and C: • To determine the safety profile of etirinotecan pegol ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02312622
Study type Interventional
Source Stanford University
Contact
Status Completed
Phase Phase 2
Start date August 2015
Completion date July 2019

See also
  Status Clinical Trial Phase
Terminated NCT01217411 - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Phase 1
Completed NCT00098605 - Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases Phase 2
Completed NCT00072163 - Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma Phase 2
Completed NCT01703507 - Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Phase 1
Completed NCT00033254 - Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases Phase 3
Active, not recruiting NCT01706432 - Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
Recruiting NCT01891318 - Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study Phase 1/Phase 2
Active, not recruiting NCT02107755 - Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma Phase 2
Suspended NCT01843413 - Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases N/A
Completed NCT01276210 - Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases Phase 1
Completed NCT01234740 - Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases Phase 1
Terminated NCT00937482 - Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer Phase 1
Terminated NCT02269111 - Quantitative MRI in Assessing Disease in Patients With Brain Tumors N/A
Withdrawn NCT02277561 - Voxel Based Diffusion Tensor Imaging in Predicting Response in Patients With Brain Metastases Undergoing Whole Brain Radiation Therapy or Stereotactic Radiosurgery N/A
Completed NCT00992602 - Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer Phase 2
Withdrawn NCT02145910 - Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases Phase 1